SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-327299
Filing Date
2021-11-12
Accepted
2021-11-12 07:10:32
Documents
13
Period of Report
2021-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d254416d8k.htm   iXBRL 8-K 25742
2 EX-99.1 d254416dex991.htm EX-99.1 51672
  Complete submission text file 0001193125-21-327299.txt   215109

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cmpi-20211112.xsd EX-101.SCH 2913
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmpi-20211112_lab.xml EX-101.LAB 19657
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmpi-20211112_pre.xml EX-101.PRE 12329
6 EXTRACTED XBRL INSTANCE DOCUMENT d254416d8k_htm.xml XML 3627
Mailing Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Business Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 978-503-2124
Checkmate Pharmaceuticals, Inc. (Filer) CIK: 0001651431 (see all company filings)

IRS No.: 364813934 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39425 | Film No.: 211399510
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences